Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Little Green Pharma Ltd. ( (AU:LGP) ) has shared an update.
Little Green Pharma Ltd has updated the timetable for its proposed acquisition of Cannatrek Ltd, confirming that the Federal Court of Australia has adjourned the second court hearing to 25 May 2026. The company has set new key dates for shareholder proxy submissions, voting eligibility, the shareholder meeting, the court approval, and the scheme implementation, with consideration securities now expected to be issued on 1 June 2026.
The revised schedule provides clearer visibility for shareholders and other stakeholders on the remaining steps required to complete the Cannatrek transaction. If completed as planned, the scheme is expected to consolidate Little Green Pharma’s position in the global medicinal cannabis market by integrating Cannatrek’s operations and aligning both businesses under a single listed entity.
The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.
More about Little Green Pharma Ltd.
Little Green Pharma Ltd is a global medicinal cannabis company with vertically integrated operations across Europe and Australia. It produces and distributes a portfolio of cannabis-based medicines through wholesalers, pharmacies, clinics, and GPs in Australia and over a dozen export markets, and also operates a domestic Health House distribution business to capture value across the supply chain.
Average Trading Volume: 137,789
Technical Sentiment Signal: Sell
Current Market Cap: A$29.06M
For an in-depth examination of LGP stock, go to TipRanks’ Overview page.